Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allakos Inc (NQ: ALLK )

0.7539 +0.0639 (+9.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 334,584
Open 0.6900
Bid (Size) 0.7103 (13)
Ask (Size) 0.7934 (4)
Prev. Close 0.6900
Today's Range 0.6750 - 0.7545
52wk Range 0.6856 - 5.640
Shares Outstanding 86,560,315
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Allakos Announces Positive Results from its Ongoing Phase 1 Trial of AK006 in Healthy Volunteers, with AK006 Demonstrating High Receptor Occupancy on Mast Cells and a Favorable Safety Profile
From Allakos Inc.
Via GlobeNewswire
Allakos Announces First Patient Dosed in Phase 1 Trial of AK006 in Chronic Spontaneous Urticaria
From Allakos Inc.
Via GlobeNewswire

Performance

YTD
-72.49%
-72.49%
1 Month
-32.08%
-32.08%
3 Month
-28.88%
-28.88%
6 Month
-37.69%
-37.69%
1 Year
-84.19%
-84.19%

More News

Read More
ALLK Stock Earnings: Allakos Meets EPS for Q1 2024
Via InvestorPlace
Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
From Allakos Inc.
Via GlobeNewswire
ALLK Stock Earnings: Allakos Misses EPS for Q4 2023
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
3 Biotech Stocks to Dump Before They Go to Zero
Via InvestorPlace
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Allakos Inc.
Via GlobeNewswire
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
From Allakos Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
From Allakos Inc.
Via GlobeNewswire
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Gold Down 1%; PNC Financial Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Crude Oil Edges Lower; Morgan Stanley Posts Upbeat Revenue
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Is Allakos (ALLK) Stock Down 57% Today?
Via InvestorPlace
Trial Setback: Allakos Drops Lead Skin Disorder Candidate, Cuts Workforce By 50%
Via Benzinga
Dow Dips 200 Points; Goldman Sachs Earnings Top Views
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Allakos Announces a Restructuring to Focus on Development of AK006
From Allakos Inc.
Via GlobeNewswire
Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
From Allakos Inc.
Via GlobeNewswire
Allakos Analyst Turns Bullish, Sees 'Significant Upside' If Study Results Are Positive
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.